文献速递肿瘤 PET/CT

术前[18F]FDG PET/CT肿瘤异质性指数在子宫平滑肌肉瘤患者中的预后价值:一项多中心回顾性研究

Preoperative [18F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-28

该多中心回顾性研究纳入16例子宫平滑肌肉瘤患者,评估术前[18F]FDG PET/CT参数(SUVmax、MTV、总病灶糖酵解)及基于MTV线性回归斜率负值(nMLRS,SUV阈值2.5和3.0)的肿瘤异质性指数的预后价值。中位术后随访21个月(范围4-82个月),12例(75.0%)复发。肿瘤大小(P=0.017)、SUVmax(P=0.019)、MTV(P=0.016)和nMLRS(P=0.008)是复发的显著预后因素;MTV(P=0.048)和nMLRS(P=0.045)是患者生存的显著预后因素。按nMLRS截断值分组的患者无进展生存(P=0.033)和总生存(P=0.044)差异显著。作者认为术前肿瘤异质性指数可能是有用的预后标志物。

要点

  • 术前[18F]FDG PET/CT的nMLRS与子宫平滑肌肉瘤复发显著相关(P=0.008)。
  • nMLRS与肿瘤大小(γ=0.825,P<0.001)和淋巴结转移(γ=0.721,P=0.004)相关。
  • 按nMLRS截断值分组,无进展生存(P=0.033)和总生存(P=0.044)差异显著。

核心结论

  • 术前通过MTV线性回归斜率获得的肿瘤异质性指数可能是子宫平滑肌肉瘤的一种新颖且有价值的预后标志物。

研究设计与样本

  • 多中心回顾性研究,纳入三家三级转诊医院接受术前[18F]FDG PET/CT的子宫平滑肌肉瘤患者16例。

主要发现

  • 中位术后随访21个月(范围4-82个月),12例(75.0%)出现复发。
  • 肿瘤大小(P=0.017)、SUVmax(P=0.019)、MTV(P=0.016)和nMLRS(P=0.008)是复发的显著预后因素。
  • MTV(P=0.048)和nMLRS(P=0.045)是患者生存的显著预后因素。
  • nMLRS与肿瘤大小相关(Pearson相关系数γ=0.825,P<0.001),与淋巴结转移相关(γ=0.721,P=0.004)。
  • 按nMLRS截断值分组的患者无进展生存(P=0.033)和总生存(P=0.044)差异显著。

关键数值与推荐

  • nMLRS定义为根据SUV阈值2.5和3.0确定的MTV线性回归斜率的负值,作为肿瘤异质性指数。
  • PET/CT参数包括原发肿瘤最大标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)和总病灶糖酵解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the prognostic value of the tumour heterogeneity index determined on preoperative [18F]FDG PET/CT in patients with uterine leiomyosarcoma (LMS). METHODS: We retrospectively reviewed patients with uterine LMS who underwent preoperative [18F]FDG PET/CT scans at three tertiary referral hospitals. The PET/CT parameters maximum standardized uptake value of the primary tumour (SUVmax), metabolic tumour volume (MTV) and total lesion glycolysis were assessed. The negative values of the MTV linear regression slope (nMLRS) according to the SUV thresholds of 2.5 and 3.0 were determined as the tumour heterogeneity index. The value of PET/CT-derived parameters in predicting progression-free survival (PFS) and overall survival (OS) were determined in regression analyses. RESULTS: Clinicopathological and PET/CT data from 16 patients were reviewed. The median postsurgical follow-up was 21 months (range 4-82 months), and 12 patients (75.0%) experienced recurrence. Tumour size (P = 0.017), SUVmax (P = 0.019), MTV (P = 0.016) and nMLRS (P = 0.008) were significant prognostic factors for recurrence. MTV (P = 0.048) and nMLRS (P = 0.045) were significant prognostic factors for patient survival. nMLRS was correlated with clinicopathological parameters including tumour size (Pearson's correlation coefficient γ = 0.825, P < 0.001) and lymph node metastasis (γ = 0.721, P = 0.004). Patient groups categorized according to the nMLRS cut-off value showed significant differences in PFS (P = 0.033) and OS (P = 0.044). CONCLUSION: The preoperative tumour heterogeneity index obtained using the MTV linear regression slope may be a novel and useful prognostic marker in uterine LMS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lee JW, Park JY, Lee HJ, et al. Preoperative [18F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study. Eur J Nucl Med Mol Imaging. 2018. PMID: 29492644. doi:10.1007/s00259-018-3975-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。